As mentioned earlier, treatment with MSCs has the potential to reduce cytokine production associated with COVID-19-induced acute respiratory distress syndrome by targeting the molecular cascade of the NF-κB/NLRP3 pathway [35,36]. This evidence concerns the gene NFKB1 and COVID-19.